Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study.

Matteo SantoniFrancesco MassariEnrique GrandeGiuseppe ProcopioMarc R MatranaMimma RizzoUgo De GiorgiUmberto BassoMichele MilellaRoberto IacovelliGaetano AurilioLorena IncorvaiaSebastiano ButiOrazio CaffoGiuseppe FornariniFrancesco CarrozzaVeronica MollicaAlessandro RizzoFady FaragJavier Molina-CerrilloNicola Battelli

Published in: Targeted oncology (2021)

Our data show that cabozantinib is active in pretreated patients with sarcomatoid renal cell carcinoma. Biomarkers are needed in this field to select patients for multi-kinase inhibitors or other options.

Keyphrases

metastatic renal cell carcinoma
renal cell carcinoma
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
big data
deep learning